Evidence map›Paper›PMID 32871161›Full record

ArticleDevelopmental and comparative immunology2021

Unaltered influenza disease outcomes in swine prophylactically treated with α-galactosylceramide.

Weihong Gu, Darling Melany D Madrid, Guan Yang, Bianca L Artiaga, Julia C Loeb, William L Castleman, Jürgen A Richt, John A Lednicky, John P Driver

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Developmental and comparative immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Weihong GuDepartment of Animal Sciences, University of Florida, Gainesville, FL, USA.
Darling Melany D MadridDepartment of Animal Sciences, University of Florida, Gainesville, FL, USA.
Guan YangDepartment of Animal Sciences, University of Florida, Gainesville, FL, USA.
Bianca L ArtiagaDepartment of Animal Sciences, University of Florida, Gainesville, FL, USA.
Julia C LoebEmerging Pathogens Institute, University of Florida, Gainesville, FL, USA.
William L CastlemanCollege of Veterinary Medicine, University of Florida, Gainesville, FL, USA.
Jürgen A RichtDepartment of Diagnostic Medicine/Pathobiology and Center of Excellence for Emerging and Zoonotic Animal Diseases (CEEZAD), College of Veterinary Medicine, Kansas State University, Manhattan, KS, USA.
John A LednickyEmerging Pathogens Institute, University of Florida, Gainesville, FL, USA; Department of Environmental and Global Health, University of Florida, Gainesville, FL, USA.
John P DriverDepartment of Animal Sciences, University of Florida, Gainesville, FL, USA. Electronic address: jdriver@ufl.edu.
University of Florida · USKansas State University · USUniversity of Florida Health · US

Funding

Harnessing Natural Killer T cells to counteract swine influenzaR01HD092286 · NICHD · UNIVERSITY OF MISSOURI-COLUMBIA · PI DRIVER, JOHN · 2017 to 2021
$2.6M
NIAID NIH HHS HHSN272201300006CNICHD NIH HHS R01 HD092286
6 · The paper itself

Abstract

Influenza A viruses (IAV) are a major cause of respiratory diseases in pigs. Invariant natural killer T (iNKT) cells are an innate-like T cell subset that contribute significantly to IAV resistance in mice. In the current work, we explored whether expanding and activating iNKT cells with the iNKT cell superagonist α-galactosylceramide (α-GalCer) would change the course of an IAV infection in pigs. In one study, α-GalCer was administered to pigs intramuscularly (i.m.) 9 days before infection, which systemically expanded iNKT cells. In another study, α-GalCer was administered intranasally (i.n.) 2 days before virus infection to activate mucosal iNKT cells. Despite a synergistic increase in iNKT cells when α-GalCer i.m. treated pigs were infected with IAV, neither approach reduced disease signs, lung pathology, or virus replication. Our results indicate that prophylactic use of iNKT cell agonists to prevent IAV infection is ineffective in pigs. This is significant because this type of approach has been considered for humans whose iNKT cell levels and IAV infections are more similar to those of pigs than mice.

Indexed as

AnimalsGalactosylceramidesHumansInfluenza A virusInfluenza, HumanInjections, IntramuscularLungLymphocyte ActivationMiceNasal MucosaNatural Killer T-CellsOrthomyxoviridae InfectionsSwineVaccine EfficacyVirus Replicationalpha-galactosylceramideGalactosylceramidesInfluenzaInvariant natural killer T cellsPigsProphylacticα-Galactosylceramide

Identifiers

PMID32871161
PMCPMC8119227
OpenAlexW3082790085

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.